From: Pharmacological characteristics and efficacy of a novel anti-angiogenic antibody FD006 in corneal neovascularization
Binding energy (kcal/mol)
Identified epitope
FD006-VEGF
-168.24
F17M18D19, Y21Q22R23, Y25, L66E67, N100K101
bevacizumab-VEGF
-156.35
F17M18D19, Y21Q22R23, Y25, K101